Welcome to our dedicated page for Emergent Biosolutions SEC filings (Ticker: EBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Emergent BioSolutions filings document an operating public-health company with NYSE-listed common stock under the symbol EBS. Its Form 8-K reports cover financial results, investor presentations, Regulation FD materials, debt prepayments, credit agreements, and other capital-structure events tied to its term loan and asset-based revolving facility.
Proxy and annual-meeting filings describe board elections, director appointments, committee service, auditor ratification, executive compensation, equity awards, and stockholder voting results. The filing record also captures governance disclosures for a company supplying NARCAN® Nasal Spray, ACAM2000®, and other medical countermeasure and bioservices products.
Lowry Simon C reported acquisition or exercise transactions in this Form 4 filing.
Emergent BioSolutions Inc. granted SVP, R&D, CMO Simon C. Lowry 100,111 shares of common stock in the form of restricted stock units. The award was approved by the Compensation Committee on March 2, 2026 and became effective after stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
The restricted stock units vest in three annual installments beginning on the anniversary of the approval date, assuming continued service. Each unit entitles Lowry to receive one share of common stock, bringing his direct holdings to 177,914 shares after the grant.
Glessner Coleen reported acquisition or exercise transactions in this Form 4 filing.
Emergent BioSolutions Inc. reported that EVP of Quality & Ethics and CPL, Coleen Glessner, received a grant of 100,111 restricted stock units of common stock at no cost. The grant was approved by the Compensation Committee on March 2, 2026, contingent on stockholder approval of an Amended Stock Incentive Plan, which stockholders approved on April 29, 2026.
The restricted stock units vest in three annual installments beginning on the anniversary of the approval date, assuming Ms. Glessner continues her service with the company. Each unit represents one share of common stock, and following this award she holds 204,219 shares of common stock directly.
Emergent BioSolutions reported that EVP and Chief Financial Officer Richard S. Lindahl acquired 162,680 shares of common stock through a restricted stock unit grant at no cash cost. The grant was approved by the Compensation Committee on March 2, 2026, and became effective after stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
The restricted stock units vest in three annual installments beginning on the anniversary of the approval date, contingent on continued service. Following this award, Lindahl directly holds 378,047 shares of Emergent BioSolutions common stock.
Emergent BioSolutions Inc. reported that SVP and General Counsel Jessica Perl received a grant of 104,282 shares of common stock in the form of restricted stock units as compensation. The grant was approved by the board’s Compensation Committee on March 2, 2026 and became effective after stockholders approved an amended stock incentive plan on April 29, 2026.
The restricted stock units vest in three equal annual installments beginning on the first anniversary of the approval date, contingent on continued service. Each restricted stock unit converts into one share of common stock, bringing Perl’s direct holdings to 165,286 shares following this award.
Hartzel William reported acquisition or exercise transactions in this Form 4 filing.
Emergent BioSolutions Inc. granted Senior Vice President of Bioservices William Hartzel 100,111 shares of Common Stock in the form of restricted stock units. The award was approved by the Compensation Committee on March 2, 2026, contingent on stockholder approval of an amended stock incentive plan.
Stockholders approved the Amended Stock Incentive Plan on April 29, 2026, allowing the grant to proceed. These restricted stock units vest in three annual installments beginning on the anniversary of the approval date, assuming continued service. After this grant, Hartzel directly holds 187,299 shares of common stock.
Emergent BioSolutions President and CEO Joseph C. Papa received a grant of 187,708 restricted stock units, approved by the Compensation Committee and stockholders under the company’s Amended Stock Incentive Plan. This equity award is a form of non-cash compensation and brings his direct holdings to 493,153 common shares.
The RSUs vest in three equal annual installments beginning on the anniversary of the approval date, assuming he continues serving at the company. Each restricted stock unit converts into one share of Emergent BioSolutions common stock upon vesting, aligning a portion of his compensation with future company performance.
Emergent BioSolutions Inc. reported weaker results for the quarter ended March 31, 2026. Total revenues were $156.1 million, down from $222.2 million, mainly from lower medical countermeasure product sales and reduced contracts and grants revenue. Gross margin fell to $61.2 million, or 41% of product and services sales.
Net income dropped to $6.8 million from $68.0 million, with diluted EPS declining to $0.07 from $1.19. Operating cash flow was a net use of $33.8 million. The company ended the quarter with $161.5 million in cash, cash equivalents and restricted cash and total debt of $589.7 million. Subsequent to quarter-end, Emergent entered a new $150 million term loan and amended its revolving credit facility, both maturing in 2031.
Emergent BioSolutions Inc. reported weaker results for the quarter ended March 31, 2026. Total revenues were $156.1 million, down from $222.2 million, mainly from lower medical countermeasure product sales and reduced contracts and grants revenue. Gross margin fell to $61.2 million, or 41% of product and services sales.
Net income dropped to $6.8 million from $68.0 million, with diluted EPS declining to $0.07 from $1.19. Operating cash flow was a net use of $33.8 million. The company ended the quarter with $161.5 million in cash, cash equivalents and restricted cash and total debt of $589.7 million. Subsequent to quarter-end, Emergent entered a new $150 million term loan and amended its revolving credit facility, both maturing in 2031.